Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.

Best practices need to be replicated, but our health care structure will make doing so more challenging, says Ace Robinson of the Fast-Track Cities initiative.

Providers, payers, and health systems need to catch up, said Melanie Thompson, M.D., at the ACTHIV conference.

As the 2019 National HIV Prevention Conference kicked off on March 18, plenary speakers discussed not only recent biomedical advances, but also what is truly needed in heavily affected U.S. communities to end the epidemic.

A dial-in hotline program in New York City has helped qualified patients access post-exposure prophylaxis (PEP) at their local pharmacies, raising the possibility that remote screening methods could be an important way to bolster PEP use.

Three new trials of HIV prevention drugs seek to answer directly a question that researchers inside and outside the field of HIV have explicitly avoided for years: How do drugs work -- and are they safe -- in pregnant and breastfeeding women?

Alicia Garza talks with TheBodyPRO's Kenyon Farrow about HIV's relative invisibility in black social justice spaces, despite its disproportionate impact on black communities.

2017 could have been worse. Although propelled to power by blustery threats to cut or eliminate publicly funded programs, including those that keep people living with HIV alive and well, the new administration has largely been unable to convert rheto...

"The stigma, fear and ignorance associated with HIV are still very strong; those of us who do this work on a daily basis might forget this sad fact," Paul Sax, M.D., writes.

"The line between government interests and community interests is completely fuzzy in the HIV universe," says Demetre Daskalakis, M.D., M.P.H.